Meet the Team

team_image

Giovanni Politi

Co-founder

After working in Italy in greenhouse aeroponic cultures, in 1989 he started working at the Finnish pharmaceutical company Orion Yhtymä Oy (now the Orion Corporation) and after two years he became head of the tablet production department. As a member of the developing group in the same department, he helped make radical changes in different fields, including the reformulation of about 200 products and the development of new production processes. From 2005 to 2008 at Atacama Oy, he managed the development of its main invention, namely the PDG technology, while from 2008 he continued the development and research of the new AGS system.

team_image

Carlo Vanoli

partner

Graduated Chemical Engineer
Senior consultant in McKinsey and Co.
Past CEO, Managing Director and Corporate Development VP in several Medical Technology companies
Managed > 10 international M&A deals, in aggregate worth in excess of € 1,5 Billion
Co-founder and current Chairman of Medeor Associates srl, a business advisory and private investment firm specialized in Health Care
Past and current Board member in several biotech and medtech companies (some listed on the stock exchange)

team_image

Vincenzo Politi

Co-founder

Thirty years of experience in the research and development of new drugs at the Italian pharmaceutical company Polifarma, where he was also responsible for licensing-out activities. The research managed by Politi concentrated on small metalloproteinase-inhibitor peptides, found in snake venom, and on human endogenous metabolites, capable of activating physio-pharmacological functions.

team_image

Edoardo Bosio

partner

team_image

Francesco Politi

Chief Financial Officer

Vincenzo’s son, has fifteen years of experience in tax management, working at various consulting companies in the USA and United Kingdom.

team_image

Ivan Veronese

partner

Ivan has an extensive experience – 40+ years - in the pharmaceutical industry of which more than 20 as the CEO of a company specializing in controlled release oral formulations. He is conversant with pharmaceutical technologies and processes. Lately he has been active in the area of M&A as partner at Medeor Associates, Milan Italy, a boutique advisory company whose main activity is to identify and promote investment projects, acting also as co-investor.